TNFRSF11A and bone metastasis: In case of anti-RANKL therapy with Denosumab in MBC patients, the increase in RANK-positive CTCs from baseline to day 2 [342] as well as the persistence of RANK-positive CTCs was related to a longer time to progress of the bone metastasis [342].